spacer
home > pmps > autumn 2003 > emerging novel liquid delivery systems
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Emerging Novel Liquid Delivery Systems

The inhalation of liquid droplets has been studied and developed since the mid 1840s when Charriere in France constructed the first liquid pulverisation device (nebuliser) for Sales-Girons. This triggered the development of smaller and more convenient table top jet nebuliser devices. In the early 20th Century these were adapted into hand-held, glass blown devices powered by a rubber 'herons' ball operated by the user. In the mid 1940s small electrical compressors were becoming more available and in the early 1960s the plastic jet nebuliser was developed. At the same time the development of ultrasonic nebulisers took place. During the mid 1990s hand-held and battery-operated ultrasonic nebulisers were marketed, such as the Omron NE-U03.

Simultaneously scientists and companies were developing and exploring novel technologies for liquid drug delivery. These technologies have been directed to replace and reduce current conventional jet and ultrasonic nebulisers' therapy and treatment time, which is often between five and 10 minutes. Recent focus has been on competing with pMDI and DPI therapy where the treatment consists of one or more inhalations. To date, there have been few devices marketed in the conventional jet and ultrasonic segment, only Omron and Aerogen have presented devices built on non conventional jet and ultrasonic technology (Omron's NE-U14, NE-U22 and NE-U03 and Aerogen has lately marketed their AeroNeb® and AeroNeb pro®). The only device competing with the pMDI/DPI segment that has been approved but not yet marketed is Boehringer Ingelheim's Respimat® softmist inhaler. This device is approved in the Netherlands but not marketed yet. It is probably awaiting EC mutual recognition before its European launch.

This article will give an overview of the current novel liquid inhalation technologies from a technical point of view and focus on technologies that are similar to the pMDIs and DPIs in their function. It will include a review of nine companies working with novel technologies for single inhalation liquid administration and three with potential technologies that can be used in this area.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ola Nerbrink, Principal Scientist, Novo Nordisk A/S, Hillerшd, Denmark

Dr Nerbrink is a Principal Scientist at Novo Nordisk A/S in Hillerшd, Denmark. He obtained a Bachelors degree in chemistry/physics from Lunds University in Sweden in 1981, a Licentiate degree in Occupational Hygiene with emphasis on inhalation topics from Lund University in 1997 and in 2001 he gained a PhD in Occupational Medicine from Karolinska Institute in Stockholm. Dr Nerbrink has been active in the pharmaceutical field for more than 19 years. He was employed at AstraZeneca R&D Lund in 1985 where he worked with aerosol-related development in the pre-clinical and pharmaceutical area as a Laboratory Scientist and later as Research Scientist.

In 1986 he was employed as an Associate Director and then Principal Scientist where he focused mainly on novel powder and liquid device development at the pharmaceutical department of AstraZeneca, with specific interest in current and future liquid aerosolisation technology. Since 2002 he has been employed by Novo Nordisk A/S in Hillerшd as a Principal Scientist where he works on the research/development of liquid atomisation systems.

spacer
Dr Ola Nerbrink
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement